Arca Biopharma Stock Today

ABIO -  USA Stock  

USD 2.02  0.02  0.98%

Market Performance
0 of 100
Odds Of Distress
Less than 5
Arca Biopharma is selling for 2.02 as of the 16th of January 2022. This is a -0.98 percent decrease since the beginning of the trading day. The stock's open price was 2.04. Arca Biopharma has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. Equity ratings for Arca Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of December 2021 and ending today, the 16th of January 2022. Please note, there could be an existing legal relationship between Arca Biopharma (ABIO) and ARCA Biopharma (NUVO). Click here to learn more.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.41 M outstanding shares of which 368.19 K shares are presently shorted by private and institutional investors with about 1.15 trading days to cover. More on Arca Biopharma

Arca Biopharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Arca Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arca Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Arca Biopharma generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (18.77 M) with profit before overhead, payroll, taxes, and interest of 28.37 M.
Arca Biopharma currently holds about 58.31 M in cash with (16.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Arca Biopharma has a frail financial position based on the latest SEC disclosures
Latest headline from 4 Solid Retail Stocks to Buy in a Challenging Industry - Nasdaq
Arca Biopharma Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Arca Biopharma SEC Filings
Arca Biopharma SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameArca Biopharma
New SymbolABIO1
Related EntityNUVO (ARCA Biopharma)
President CEO, DirectorMichael Bristow  (View All)
Average Analyst Recommendation
Analysts covering Arca Biopharma report their recommendations after researching Arca Biopharma's financial statements, talking to executives and customers, or listening in on Arca Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Arca Biopharma. The Arca Biopharma consensus assessment is calculated by taking the average forecast from all of the analysts covering Arca Biopharma.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Arca Biopharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Arca Biopharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares5.8 M5.4 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted5.8 M5.4 M
Significantly Up
Slightly volatile
Total Assets62.6 M58 M
Significantly Up
Slightly volatile
Total Liabilities4.8 M4.5 M
Significantly Up
Slightly volatile
Current Assets62 M57.5 M
Significantly Up
Slightly volatile
Current Liabilities4.3 MM
Significantly Up
Slightly volatile
Total Debt365.9 K368.1 K
Slightly Down
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Arca Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Arca Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Arca Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arca Biopharma's financial leverage. It provides some insight into what part of Arca Biopharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Arca Biopharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Arca Biopharma deploys its capital and how much of that capital is borrowed.
Arca Biopharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 507 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Arca Biopharma has a current ratio of 18.38, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(7.5 Million)Share
Arca Biopharma (ABIO) is traded on NASDAQ Exchange in USA. It is located in 10170 Church Ranch Way and employs 11 people. Arca Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 29.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arca Biopharma's market, we take the total number of its shares issued and multiply it by Arca Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Arca Biopharma conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 14.41 M outstanding shares of which 368.19 K shares are presently shorted by private and institutional investors with about 1.15 trading days to cover. Arca Biopharma currently holds about 58.31 M in cash with (16.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Arca Biopharma Probability Of Bankruptcy
The market capitalization of Arca Biopharma is $29.4 Million. Almost 89.0 percent of Arca Biopharma outstanding shares are held by regular investors with 0.74 (percent) owned by insiders and only 10.61 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Arca Biopharma Ownership Details

Arca Biopharma Stock Price Odds Analysis

What are Arca Biopharma's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Arca Biopharma jumping above the current price in 90 days from now is over 95.5%. The Arca Biopharma probability density function shows the probability of Arca Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Arca Biopharma has a beta of 0.0565. This suggests as returns on the market go up, Arca Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Arca Biopharma will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Arca Biopharma is significantly underperforming DOW.
 Odds Down 2.02HorizonTargetOdds Up 2.02 
4.46%90 days
Based on a normal probability distribution, the odds of Arca Biopharma to move above the current price in 90 days from now is over 95.5 (This Arca Biopharma probability density function shows the probability of Arca Biopharma Stock to fall within a particular range of prices over 90 days) .

Arca Biopharma Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Arca Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arca Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arca Biopharma's value.
InstituionSecurity TypeTotal SharesValue
Gsa Capital Partners LlpCommon Shares441.9 K1.3 M
Vanguard Group IncCommon Shares417.3 K1.2 M
Susquehanna International Group LlpPut Options73.1 K216 K
Group One Trading LpCall Options3.5 K10 K
View Arca Biopharma Diagnostics

Arca Biopharma Historical Income Statement

Arca Biopharma Income Statement is one of the three primary financial statements used for reporting Arca Biopharma's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Arca Biopharma revenue and expense. Arca Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Arca Biopharma Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 11.63 Million. Research and Development Expense is expected to rise to about 6.3 M this year, although the value of Consolidated Income will most likely fall to (9.5 M). View More Fundamentals

Arca Biopharma Stock Against Markets

Picking the right benchmark for Arca Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arca Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arca Biopharma is critical whether you are bullish or bearish towards Arca Biopharma at a given time.

Similar Equity Warning - ABIO

Arca Biopharma was forked

The entity Arca Biopharma with a symbol ABIO was recently forked. You can potentially use Applied Biometrics with a symbol ABIO1 from now on.

Arca Biopharma Corporate Directors

Arca Biopharma corporate directors refer to members of an Arca Biopharma board of directors. The board of directors generally takes responsibility for the Arca Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arca Biopharma's board members must vote for the resolution. The Arca Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Raymond Woosley - DirectorProfile
Daniel Mitchell - DirectorProfile
Linda Grais - Lead Independent DirectorProfile
Anders Hove - DirectorProfile
Please continue to Trending Equities. Note that the Arca Biopharma information on this page should be used as a complementary analysis to other Arca Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Arca Biopharma Stock analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEO Directory
Screen CEOs from public companies around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.